{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:04:28Z","timestamp":1784394268694,"version":"3.55.0"},"posted":{"date-parts":[[2026,7,16]]},"group-title":"Microbiology","reference-count":88,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                  (\n                  <jats:italic>Ng<\/jats:italic>\n                  ) is the causative agent of gonorrhea, and the global spread of antimicrobial-resistant strains makes vaccine development a public health priority. Although messenger RNA (mRNA) vaccines have transformed protection against viral diseases, the platform remains in its infancy against pathogenic bacteria. Here, we evaluated the immunogenicity and protective efficacy of an mRNA\u2013lipid nanoparticle (LNP) vaccine encoding the highly conserved outer membrane antigen BamA in the female mouse model of lower genital tract infection. We delivered BamA mRNA-LNPs via intramuscular (IM) or intranasal (IN) routes, with or without CpG ODN 2395, and measured antigen-specific antibody responses in serum and vaginal lavage samples. Both routes elicited robust BamA-specific antibodies that recognized diverse\n                  <jats:italic>Ng<\/jats:italic>\n                  isolates, including ceftriaxone-resistant strains. However, neither route accelerated bacterial clearance nor reduced bioburden, nor did either generate serum bactericidal activity. These findings show that BamA mRNA-LNPs are immunogenic but, as formulated, are not protective, and they pave the way for modifications to the construct, adjuvant, and route. To our knowledge, this is the first evaluation of an mRNA vaccine against\n                  <jats:italic>Ng<\/jats:italic>\n                  , establishing the platform as an amenable approach for gonococcal antigen testing.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>Importance<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                    is a high-priority public health threat, and no licensed gonococcal vaccine exists. mRNA-lipid nanoparticle vaccines have transformed antiviral immunization but remain largely untested against bacterial pathogens. This study is the first to evaluate an mRNA vaccine against\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    , using the conserved, essential outer membrane antigen BamA. We show that BamA mRNA-LNPs delivered by intramuscular or intranasal routes elicit robust, broadly cross-reactive antibodies that recognize diverse isolates, including ceftriaxone-resistant strains, even though the tested formulations did not confer protection in mice. By establishing mRNA-LNPs as a viable platform for gonococcal antigen testing, this work lays the foundation for optimizing constructs, adjuvants, and routes for developing mRNA-based vaccines against gonorrhea and other antimicrobial-resistant bacteria.\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.07.14.738439","type":"posted-content","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:50:12Z","timestamp":1784260212000},"source":"Crossref","is-referenced-by-count":0,"title":["An mRNA\u2013Lipid Nanoparticle Platform Encoding the Conserved Outer Membrane Protein BamA Elicits Broadly Cross-Reactive Systemic and Mucosal Antibodies Against Antimicrobial-Resistant\n                  <i>Neisseria gonorrhoeae<\/i>"],"prefix":"10.64898","author":[{"given":"Natalie","family":"Wolske","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namratha Turuvekere Vittala","family":"Murthy","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon, United States"},{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon Health & Science University, Portland, Oregon, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Chanda","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid","family":"Nazir","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryszard A.","family":"Zielke","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian G.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeonghwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon, United States"},{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon Health & Science University, Portland, Oregon, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Kant","sequence":"additional","affiliation":[{"name":"Computational Drug & Vaccine Discovery Laboratory, Faculty of Applied Sciences & Biotechnology, Shoolini University, Solan, Himachal Pradesh-173229, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Sahay","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon, United States"},{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon Health & Science University, Portland, Oregon, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7977-2596","authenticated-orcid":false,"given":"Aleksandra E.","family":"Sikora","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon, United States"},{"name":"Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026071809450633000_2026.07.14.738439v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02444-3"},{"key":"2026071809450633000_2026.07.14.738439v1.2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00594"},{"key":"2026071809450633000_2026.07.14.738439v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01294-2"},{"key":"2026071809450633000_2026.07.14.738439v1.4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.885371"},{"key":"2026071809450633000_2026.07.14.738439v1.5","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41564-025-02070-z","article-title":"Challenges and opportunities in mRNA vaccine development against bacteria","volume":"10","year":"2025","journal-title":"Nat Microbiol"},{"key":"2026071809450633000_2026.07.14.738439v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00283-5"},{"key":"2026071809450633000_2026.07.14.738439v1.7","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-10-77"},{"key":"2026071809450633000_2026.07.14.738439v1.8","doi-asserted-by":"crossref","unstructured":"Lukeman H , Al-Wassiti H , Fabb SA , Lim L , Wang T , Britton WJ , Steain M , Pouton CW , Triccas JA , Counoupas C . 2025. An LNP-mRNA vaccine modulates innate cell trafficking and promotes polyfunctional Th1 CD4+ T cell responses to enhance BCG- induced protective immunity against Mycobacterium tuberculosis. eBioMedicine 113.","DOI":"10.1016\/j.ebiom.2025.105599"},{"key":"2026071809450633000_2026.07.14.738439v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.07.022"},{"key":"2026071809450633000_2026.07.14.738439v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.11.040"},{"key":"2026071809450633000_2026.07.14.738439v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.04.043"},{"key":"2026071809450633000_2026.07.14.738439v1.12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41541-024-00890-4","article-title":"Multivalent mRNA-DTP vaccines are immunogenic and provide protection from Bordetella pertussis challenge in mice","volume":"9","year":"2024","journal-title":"NPJ Vaccines"},{"key":"2026071809450633000_2026.07.14.738439v1.13","doi-asserted-by":"crossref","unstructured":"Kon E , Levy Y , Elia U , Cohen H , Hazan-Halevy I , Aftalion M , Ezra A , Bar-Haim E , Naidu GS , Diesendruck Y , Rotem S , Ad-El N , Goldsmith M , Mamroud E , Peer D , Cohen O . 2023. A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium. Sci Adv 9:eadg1036.","DOI":"10.1126\/sciadv.adg1036"},{"key":"2026071809450633000_2026.07.14.738439v1.14","doi-asserted-by":"crossref","unstructured":"Shattock RJ , Andrianaivoarimanana V , McKay PF , Randriantseheno LN , Murugaiah V , Samnuan K , Rogers P , Tregoning JS , Rajerison M , Moore KM , Laws TR , Williamson ED. 2023. A self-amplifying RNA vaccine provides protection in a murine model of bubonic plague. Frontiers in microbiology 14:1247041.","DOI":"10.3389\/fmicb.2023.1247041"},{"key":"2026071809450633000_2026.07.14.738439v1.15","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn4955"},{"key":"2026071809450633000_2026.07.14.738439v1.16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41541-023-00672-4","article-title":"Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa","volume":"8","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2026071809450633000_2026.07.14.738439v1.17","doi-asserted-by":"crossref","unstructured":"Huang T , Che S , Lv Z , Hao D , Wang R , Yi Q , Mei L , Yuan Y , Zou H , Guo Y , Wang X , Chu Y , Zhao K. 2025. mRNA-LNP vaccines combined with tPA signal sequence elicit strong protective immunity against Klebsiella pneumoniae . mSphere 10:e00775-24.","DOI":"10.1128\/msphere.00775-24"},{"key":"2026071809450633000_2026.07.14.738439v1.18","doi-asserted-by":"crossref","first-page":"102699","DOI":"10.1016\/j.omtn.2025.102699","article-title":"Development of a novel-ionizable-lipid- based mRNA vaccine for broad protection against Streptococcus pneumoniae","volume":"36","year":"2025","journal-title":"Molecular Therapy Nucleic Acids"},{"key":"2026071809450633000_2026.07.14.738439v1.19","unstructured":"World Health Organization. 2023. Gonorrhoea (Neisseria gonorrhoeae infection) https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/gonorrhoea-(neisseria-gonorrhoeae-infection)."},{"key":"2026071809450633000_2026.07.14.738439v1.20","unstructured":"WHO. 2023. Multi-drug resistant gonorrhea."},{"key":"2026071809450633000_2026.07.14.738439v1.21","unstructured":"WHO. 2024. WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance."},{"key":"2026071809450633000_2026.07.14.738439v1.22","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00094-23"},{"key":"2026071809450633000_2026.07.14.738439v1.23","doi-asserted-by":"crossref","unstructured":"Sancta St. Cyr ; Lindley Barbee ; Kimberly A. Workowski ; Laura H. Bachmann ; Cau Pham ; Karen Schlanger ; Elizabeth Torrone ; Hillard Weinstock ; Ellen N. Kersh ; Phoebe Thorpe . 2020. Update to CDC\u2019s Treatment Guidelines for Gonococcal Infection. MMWR Morb Mortal Wkly Rep 69:1911\u20131916.","DOI":"10.15585\/mmwr.mm6950a6"},{"key":"2026071809450633000_2026.07.14.738439v1.24","unstructured":"The U. S. Food and Drug Administration. 2025. FDA Approves Two Oral Therapies to Treat Gonorrhea."},{"key":"2026071809450633000_2026.07.14.738439v1.25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41541-026-01410-2","article-title":"Gonococcal outer membrane vesicle vaccines: bacterial population biology, clinical trials, immune profiling, and vaccine design","volume":"11","year":"2026","journal-title":"NPJ Vaccines"},{"key":"2026071809450633000_2026.07.14.738439v1.26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-026-01417-9","article-title":"Perspective on the pathogenic Neisseria: milestones, challenges, and future directions","volume":"11","year":"2026","journal-title":"NPJ Vaccines"},{"key":"2026071809450633000_2026.07.14.738439v1.27","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00245-23"},{"key":"2026071809450633000_2026.07.14.738439v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31449-6"},{"key":"2026071809450633000_2026.07.14.738439v1.29","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae383"},{"key":"2026071809450633000_2026.07.14.738439v1.30","unstructured":"NHS England. 2025. NHS and local government to roll out world-first vaccine programme to prevent gonorrhoea."},{"key":"2026071809450633000_2026.07.14.738439v1.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008602"},{"key":"2026071809450633000_2026.07.14.738439v1.32","doi-asserted-by":"crossref","unstructured":"Baarda BI , Zielke RA , Holm AK , Sikora AE. 2021. Comprehensive Bioinformatic Assessments of the Variability of Neisseria gonorrhoeae Vaccine Candidates. mSphere 6.","DOI":"10.1128\/mSphere.00977-20"},{"key":"2026071809450633000_2026.07.14.738439v1.33","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.RA118.001125"},{"key":"2026071809450633000_2026.07.14.738439v1.34","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M116.058800"},{"issue":"1F","key":"2026071809450633000_2026.07.14.738439v1.35","first-page":"3","article-title":"Quantitative proteomic analysis of the cell envelopes and native membrane vesicles derived from gram-negative bacteria","volume":"34","year":"2014","journal-title":"Current protocols in microbiology"},{"key":"2026071809450633000_2026.07.14.738439v1.36","doi-asserted-by":"publisher","DOI":"10.1038\/nature12521"},{"key":"2026071809450633000_2026.07.14.738439v1.37","doi-asserted-by":"crossref","unstructured":"Rollauer SE , Sooreshjani MA , Noinaj N , Buchanan SK . 2015. Outer membrane protein biogenesis in Gram-negative bacteria. Philos Trans R Soc Lond B Biol Sci 370.","DOI":"10.1098\/rstb.2015.0023"},{"key":"2026071809450633000_2026.07.14.738439v1.38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-8-4"},{"key":"2026071809450633000_2026.07.14.738439v1.39","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-514"},{"key":"2026071809450633000_2026.07.14.738439v1.40","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa379"},{"key":"2026071809450633000_2026.07.14.738439v1.41","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw288"},{"key":"2026071809450633000_2026.07.14.738439v1.42","doi-asserted-by":"publisher","DOI":"10.1086\/513847"},{"key":"2026071809450633000_2026.07.14.738439v1.43","doi-asserted-by":"crossref","unstructured":"Spence JM , Wright L , Clark VL . 2008. Laboratory maintenance of Neisseria gonorrhoeae. Current protocols in microbiology Chapter 4:Unit 4A 1.","DOI":"10.1002\/9780471729259.mc04a01s8"},{"key":"2026071809450633000_2026.07.14.738439v1.44","first-page":"e3998","article-title":"Optimized Recombinant Production of Secreted Proteins Using Human Embryonic Kidney (HEK293) Cells Grown in Suspension","volume":"11","year":"2021","journal-title":"Bio Protoc"},{"key":"2026071809450633000_2026.07.14.738439v1.45","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.70.1.610-612.2004"},{"key":"2026071809450633000_2026.07.14.738439v1.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.10.077"},{"key":"2026071809450633000_2026.07.14.738439v1.47","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA117.000437"},{"key":"2026071809450633000_2026.07.14.738439v1.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-44505-5"},{"issue":"4A","key":"2026071809450633000_2026.07.14.738439v1.49","first-page":"3","article-title":"Isolation of Cell Envelopes and Naturally Released Membrane Vesicles of Neisseria gonorrhoeae","volume":"34","year":"2014","journal-title":"Current protocols in microbiology"},{"key":"2026071809450633000_2026.07.14.738439v1.50","first-page":"107","article-title":"Estradiol- Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections","volume":"2","year":"2011","journal-title":"Frontiers in microbiology"},{"key":"2026071809450633000_2026.07.14.738439v1.51","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.11.5699-5708.1999"},{"key":"2026071809450633000_2026.07.14.738439v1.52","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1093\/infdis\/jiab211","article-title":"Preclinical Testing of Vaccines and Therapeutics for Gonorrhea in Female Mouse Models of Lower and Upper Reproductive Tract Infection","volume":"224","year":"2021","journal-title":"J Infect Dis"},{"key":"2026071809450633000_2026.07.14.738439v1.53","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9496-0_24"},{"key":"2026071809450633000_2026.07.14.738439v1.54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000323"},{"key":"2026071809450633000_2026.07.14.738439v1.55","doi-asserted-by":"crossref","first-page":"e0250023","DOI":"10.1128\/mbio.02500-23","article-title":"Preclinical efficacy of a cell division protein candidate gonococcal vaccine identified by artificial intelligence","volume":"14","year":"2023","journal-title":"mBio"},{"key":"2026071809450633000_2026.07.14.738439v1.56","unstructured":"Leary SU. 2020. AVMA Guidelines for the Euthanasia of Animals: 2020 Edition, 2020th ed. Schaumburg, IL."},{"key":"2026071809450633000_2026.07.14.738439v1.57","doi-asserted-by":"crossref","first-page":"e0292823","DOI":"10.1128\/mbio.02928-23","article-title":"Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity","volume":"15","year":"2024","journal-title":"mBio"},{"key":"2026071809450633000_2026.07.14.738439v1.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.03.091"},{"key":"2026071809450633000_2026.07.14.738439v1.59","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12951-024-02488-3","article-title":"Efficient signal sequence of mRNA vaccines enhances the antigen expression to expand the immune protection against viral infection","volume":"22","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"2026071809450633000_2026.07.14.738439v1.60","doi-asserted-by":"crossref","unstructured":"Pulkina A , Vasilyev K , Muzhikyan A , Sergeeva M , Romanovskaya-Romanko E , Shurygina AP , Shuklina M , Vasin A , Stukova M , Egorov A . 2023. IgGkappa Signal Peptide Enhances the Efficacy of an Influenza Vector Vaccine against Respiratory Syncytial Virus Infection in Mice. Int J Mol Sci 24.","DOI":"10.3390\/ijms241411445"},{"key":"2026071809450633000_2026.07.14.738439v1.61","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.apsb.2022.11.026","article-title":"Lipid carriers for mRNA delivery","volume":"13","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"2026071809450633000_2026.07.14.738439v1.62","doi-asserted-by":"crossref","first-page":"102083","DOI":"10.1016\/j.omtn.2023.102083","article-title":"mRNA vaccine trafficking and resulting protein expression after intramuscular administration","volume":"35","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026071809450633000_2026.07.14.738439v1.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.12.014"},{"key":"2026071809450633000_2026.07.14.738439v1.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.08.007"},{"key":"2026071809450633000_2026.07.14.738439v1.65","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00388-22"},{"key":"2026071809450633000_2026.07.14.738439v1.66","doi-asserted-by":"crossref","first-page":"2249124","DOI":"10.1080\/22221751.2023.2249124","article-title":"Th1-polarized MtrE-based gonococcal vaccines display prophylactic and therapeutic efficacy","volume":"12","year":"2023","journal-title":"Emerging Microbes & Infections"},{"key":"2026071809450633000_2026.07.14.738439v1.67","doi-asserted-by":"crossref","unstructured":"Song S , Ge H , Yuan D , Gu X , Lu W , Ding C , Qin Y , Gao S , Lin X , Cheng H , Van Der Veen S. 2026. MtrE Loop2-specific multiple antigenic peptide vaccine and monoclonal antibody confer complement-dependent protection against Neisseria gonorrhoeae. npj Vaccines 11:81.","DOI":"10.1038\/s41541-026-01412-0"},{"key":"2026071809450633000_2026.07.14.738439v1.68","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-48171-5"},{"key":"2026071809450633000_2026.07.14.738439v1.69","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/mi.2017.11","article-title":"Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model","volume":"10","year":"2017","journal-title":"Mucosal immunology"},{"key":"2026071809450633000_2026.07.14.738439v1.70","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.4049\/jimmunol.158.5.2278","article-title":"Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization","volume":"158","year":"1997","journal-title":"J Immunol"},{"key":"2026071809450633000_2026.07.14.738439v1.71","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1128\/jvi.70.9.6119-6125.1996","article-title":"Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery","volume":"70","year":"1996","journal-title":"J Virol"},{"key":"2026071809450633000_2026.07.14.738439v1.72","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e31821d0f98"},{"key":"2026071809450633000_2026.07.14.738439v1.73","doi-asserted-by":"crossref","unstructured":"Unemo M , Golparian D , Grad Y , Limnios A , Wi T , Lahra M , Harris S . 2015. Phenotypic, Genetic and Genomic Characterisation of the 2015 Who Neisseria Gonorrhoeae Reference Strains for Quality Assurance of Laboratory Investigations Globally. Sex Transm Infect 91:A111\u2013A111.","DOI":"10.1136\/sextrans-2015-052270.295"},{"key":"2026071809450633000_2026.07.14.738439v1.74","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(26)00126-X","article-title":"GoGoVax dispels hopes for gonorrhoea vaccination","volume":"26","year":"2026","journal-title":"The Lancet Infectious Diseases"},{"key":"2026071809450633000_2026.07.14.738439v1.75","first-page":"51","article-title":"Meningococcal B (4CMenB) vaccination for the prevention of gonorrhea in men who have sex with men [CROI Abstract 197]","volume":"34","year":"2026","journal-title":"Topics in Antiviral Medicine"},{"key":"2026071809450633000_2026.07.14.738439v1.76","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-026-01422-y"},{"key":"2026071809450633000_2026.07.14.738439v1.77","unstructured":"GSK. 2024. Pipeline Assets and Clinical Trials Appendix Q3 2024."},{"key":"2026071809450633000_2026.07.14.738439v1.78","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41541-025-01190-1","article-title":"A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in mice","volume":"10","year":"2025","journal-title":"NPJ Vaccines"},{"key":"2026071809450633000_2026.07.14.738439v1.79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1916131117"},{"key":"2026071809450633000_2026.07.14.738439v1.80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33721-y"},{"key":"2026071809450633000_2026.07.14.738439v1.81","doi-asserted-by":"crossref","unstructured":"Larsen SE , Erasmus JH , Reese VA , Pecor T , Archer J , Kandahar A , Hsu FC , Nicholes K , Reed SG , Baldwin SL , Coler RN . 2023. An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis. Vaccines (Basel) 11.","DOI":"10.3390\/vaccines11010130"},{"key":"2026071809450633000_2026.07.14.738439v1.82","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-025-60580-0","article-title":"An mRNA vaccine encoding five conserved Group A Streptococcus antigens","volume":"16","year":"2025","journal-title":"Nat Commun"},{"key":"2026071809450633000_2026.07.14.738439v1.83","doi-asserted-by":"crossref","first-page":"126205","DOI":"10.1016\/j.vaccine.2024.126205","article-title":"Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine","volume":"42","year":"2024","journal-title":"Vaccine"},{"key":"2026071809450633000_2026.07.14.738439v1.84","doi-asserted-by":"crossref","unstructured":"Teran-Navarro H , Salcines-Cuevas D , Calderon-Gonzalez R , Tobes R , Calvo- Montes J , P\u00e9rez-Del Molino Bernal IC , Ya\u00f1ez-Diaz S , Fresno M , Alvarez-Dominguez C. 2021. A Comparison Between Recombinant Listeria GAPDH Proteins and GAPDH Encoding mRNA Conjugated to Lipids as Cross-Reactive Vaccines for Listeria, Mycobacterium, and Streptococcus. Front Immunol 12:632304.","DOI":"10.3389\/fimmu.2021.632304"},{"key":"2026071809450633000_2026.07.14.738439v1.85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41541-019-0139-z","article-title":"An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R- and IL-17R- dependent Th1 responses","volume":"4","year":"2019","journal-title":"NPJ Vaccines"},{"key":"2026071809450633000_2026.07.14.738439v1.86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27063-4"},{"key":"2026071809450633000_2026.07.14.738439v1.87","doi-asserted-by":"crossref","unstructured":"Zielke RA , Wierzbicki IH , Baarda BI , Gafken PR , Soge OO , Holmes KK , Jerse AE , Unemo M , Sikora AE . 2016. Proteomics-driven Antigen Discovery for Development of Vaccines Against Gonorrhea - PubMed. Molecular & cellular proteomics : MCP 15.","DOI":"10.1074\/mcp.M116.058800"},{"key":"2026071809450633000_2026.07.14.738439v1.88","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1074\/mcp.M113.029538","article-title":"Quantitative proteomics of the Neisseria gonorrhoeae cell envelope and membrane vesicles for the discovery of potential therapeutic targets","volume":"13","year":"2014","journal-title":"Molecular & cellular proteomics : MCP"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.07.14.738439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T16:45:23Z","timestamp":1784393123000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.07.14.738439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":88,"URL":"https:\/\/doi.org\/10.64898\/2026.07.14.738439","relation":{},"subject":[],"published":{"date-parts":[[2026,7,16]]},"subtype":"preprint"}}